Syncromune®, Inc. Presents Innovative SYNC-T™ Combination Immunotherapy Approach at Major European Interventional Oncology ConferenceNovel procedure combines image-guided tumor cryolysis with intratumoral immunotherapy infusion, with early clinical findings in metastatic prostate cancerFORT LAUDERDALE, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company advancing SYNC-T™, an investigational platform...

Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical OfficerFORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T™, an in situ platform combination immunotherapy optimized for...